Security record · archived quarter
ZBIO
Zenas BioPharma, Inc. · Healthcare · Biotechnology
10Tracked holders
+3Δ holders
7.80MShares held
$75.56MReported value
+3New positions
−0Exits
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +5.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 58 | +3 | 32.34M | $814.38M | +8 | −5 |
| Q1 2026 | 57 | 0 | 27.25M | $547.68M | +9 | −9 |
| Q4 2025 | 56 | +4 | 18.00M | $649.25M | +4 | n/a |
| Q3 2025 | 12 | 0 | 9.51M | $211.12M | +1 | −1 |
| Q2 2025 | 10 | +3 | 7.80M | $75.56M | +3 | n/a |
| Q1 2025 | 4 | -5 | 2.01M | $15.92M | n/a | −5 |
| Q4 2024 | 9 | -1 | 2.55M | $20.73M | +1 | −2 |
| Q3 2024 | 9 | +9 | 2.41M | $40.14M | +9 | n/a |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 138 holders, 55.37M shares, $1.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2025 ·
Methodology ·
Get this via the API